Market Cap
$13.0B
ICLR
ICON PLC
$162.05 ▲ +0.12%
Prev close $161.85Market cap$13.0B
ConsensusBuy
12-mo target$186.76 (+15.3%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)Congressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on ICLR right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Buy (67%)
Insider Activity
$0.00 buy / $4.0M sell
Insider Net $
-$4.0M
SEC Reports
12
Congressional
3 trades
Price chart 30d -0.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: ICLR — 58.9% short (0.4M / 0.7M)
Short: 408,018 | Exempt: 0 | TRF Vol: 693,311 | Short Ratio: 58.9% | Off-exchange volume (dark pool
Sep 17, 2026 Insider
Murphy Ronan Martin acquired via exercise 5,005 shares
Director @ $125.74 ($629.3K)
Sep 17, 2026 Insider
Murphy Ronan Martin sold 5,005 shares
Director @ $175.00 ($875.9K)
Sep 17, 2026 Insider
Aug 20, 2026 SEC McCague Eugene Pacelli acquired via exercise 3,255 shares
Director @ $125.74 ($409.3K)
ICON plc filed its 2025 ICON Cares ESG report via a 6-K, detailing environmental, social, and governance progress. The r
6-K — Impact 2/10
Aug 14, 2026 Congress
Aug 13, 2026 SEC Kevin Hern sell
$15,001 - $50,000 — House
Seven ICON PLC insiders, including the CEO and CFO, sold a total of ~$237K in open-market sales over a one-week window.
CLUSTER — Impact 2/10
A cluster of 20 insider sales by 6 directors at ICON PLC over a single day (Aug 11, 2026) totaling ~$1.0M, plus a separa
CLUSTER — Impact 2/10
Analyst ratings buy % +15.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
67% rate it Buy or better · 24 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 18, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Jul 31, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Jul 31, 2026 | Truist Securities | REITERATE | Buy | 55% |
| Jun 30, 2026 | Truist Securities | UPGRADE | Buy | 55% |
| Jun 26, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jun 25, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Jun 25, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Jun 25, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| Jun 25, 2026 | RBC Capital | UPGRADE | Outperform | 55% |
| Jun 25, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 11 | 7 | 1 | 0 | 67% | |
| Aug 1, 2026 | 5 | 11 | 7 | 1 | 0 | 67% | |
| Jul 1, 2026 | 5 | 11 | 7 | 1 | 0 | 67% | |
| Jun 1, 2026 | 5 | 9 | 9 | 1 | 0 | 58% | |
| May 1, 2026 | 5 | 8 | 9 | 1 | 0 | 57% | |
| Apr 1, 2026 | 5 | 9 | 9 | 1 | 0 | 58% | |
| Mar 1, 2026 | 5 | 8 | 10 | 1 | 0 | 54% | |
| Feb 1, 2026 | 4 | 9 | 11 | 0 | 0 | 54% |
Price targets
Where 17 covering analysts think ICLR trades over the next 12 months.
$186.76 +15.3% upside Buy
Current$162.05 Low$155.00 Median$187.00 High$220.00 17 analysts
$155.00$220.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 5 bearish, 0 mixed, 6 neutral · avg impact 4.8/10.
NEUTRAL6-K2/10
ICON plc filed its 2025 ICON Cares ESG report via a 6-K, detailing environmental, social, and govern
Aug 20, 2026
NEUTRALCLUSTER2/10
Seven ICON PLC insiders, including the CEO and CFO, sold a total of ~$237K in open-market sales over
Aug 13, 2026
NEUTRALCLUSTER2/10
A cluster of 20 insider sales by 6 directors at ICON PLC over a single day (Aug 11, 2026) totaling ~
Aug 12, 2026
BULLISH6-K6/10
ICON plc priced $2.15 billion of senior unsecured notes via its subsidiary, with proceeds earmarked
Aug 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59
Phase Phase 2 — COMPLETED
Sep 29, 2026
short_volume
Short Volume: ICLR — 58.9% short (0.4M / 0.7M)
Short: 408,018 | Exempt: 0 | TRF Vol: 693,311 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: ICLR — 75.6% short (0.4M / 0.5M)
Short: 387,871 | Exempt: 321 | TRF Vol: 513,036 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
Clinical Trial
Anthrax AV7909 Boost Evaluation Study
Phase Phase 2 — COMPLETED
Sep 24, 2026
Clinical Trial
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.65 | $2.56–$2.70 | -19.9% | -0.9% | 1↑ 2↓ | $2.0B | 15 |
| Next Q | $2.85 | $2.69–$2.94 | 13.1% | +0.5% | 3↑ 0↓ | $2.0B | 15 |
| Current FY | $10.58 | $10.35–$10.86 | -15.6% | -0.1% | 1↑ 2↓ | $8.1B | 18 |
| Next FY | $11.82 | $10.88–$12.48 | 11.7% | -0.5% | 3↑ 1↓ | $8.4B | 18 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.652 | — |
| 7d ago | $2.655 | -0.003 |
| 30d ago | $2.676 | -0.023 |
| 60d ago | $2.678 | -0.025 |
| 90d ago | $2.707 | -0.055 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net -$4.0M — $0.00 bought, $4.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Murphy Ronan Martin | Director | EXERCISE | 5,005 | $125.74 | $629.3K |
| Sep 17, 2026 | Murphy Ronan Martin | Director | SELL | 5,005 | $175.00 | $875.9K |
| Sep 17, 2026 | McCague Eugene Pacelli | Director | EXERCISE | 3,255 | $125.74 | $409.3K |
| Sep 17, 2026 | McCague Eugene Pacelli | Director | SELL | 3,255 | $175.00 | $569.6K |
| Sep 16, 2026 | CLIMAX JOHN DR | Director | EXERCISE | 5,005 | $125.74 | $629.3K |
| Sep 16, 2026 | CLIMAX JOHN DR | Director | SELL | 5,005 | $175.00 | $875.9K |
| Aug 11, 2026 | Murphy Ronan Martin | Director | SELL | 590 | $164.47 | $97.0K |
| Aug 11, 2026 | Murphy Ronan Martin | Director | SELL | 67 | $165.51 | $11.1K |
| Aug 11, 2026 | Murphy Ronan Martin | Director | SELL | 88 | $162.72 | $14.3K |
| Aug 11, 2026 | Murphy Ronan Martin | Director | SELL | 96 | $163.77 | $15.7K |
Congressional trades
ICLR trades disclosed by members of Congress, with disclosure delay.
2 members · 0 buys / 3 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Kevin Hern | R | HOUSE | SELL | $15,001 - $50,000 | Icon PLC | Sep 2, 2026(20d) |
| Mar 5, 2026 | Kevin Hern | R | HOUSE | SELL | $100,001 - $250,000 | Icon PLC | Apr 6, 2026(33d) |
| Feb 12, 2026 | Julia Letlow | R | HOUSE | SELL | $1,001 - $15,000 | Icon PLC | Mar 13, 2026(30d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ICLR.
Shares short
2,626,654
Settlement Sep 15, 2026
Change vs prior
+10.4%
Semi-monthly cycle
Days to cover
2.8
At avg daily volume
Of shares outstanding
≈3.4%
Estimate — not % of float
All ICLR filing & press-release reports (12)
- 6-K reportAug 20, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 12, 2026
- 6-K reportAug 6, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 22, 2026
- 6-K reportJun 24, 2026
- 6-K reportJun 24, 2026
- 6-K reportJun 17, 2026
- 6-K reportMay 27, 2026
- 20-F reportMay 27, 2026
- 6-K reportMay 26, 2026